Related Experiment Video
Updated: Aug 10, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
Update on Abciximab Readministration During Percutaneous Coronary Interventions
1Division of Cardiology, Department of Medicine, Duke University Medical Center, Box 3257, Durham, NC 27710, USA. tchen001@mc.duke.edu
Abstract:
Abciximab is a monoclonal antibody fragment that blocks the platelet glycoprotein IIb/IIIa receptor and is increasingly used as an adjunct to percutaneous coronary intervention. Because some patients will return for additional revascularization procedures, it is anticipated that abciximab retreatment may be necessary. There exists at least the theoretic potential for immunologic reactions and diminished efficacy upon re-exposure to abciximab. The limited data available regarding abciximab retreatment suggests that readministration is as safe and effective as first-time treatment, provided certain precautions are taken. This review summarizes the available clinical data and provides suggestions for safe abciximab readministration.
More Related Videos
05:26Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Related Concept Videos
Cardiac Catheterization I: Pre-Procedure Overview
Cardiac Catheterization IV: Nursing Management
Acute Coronary Syndrome I: Introduction
Peripheral Artery Disease III: Interprofessional Care